On February 20, 2024, Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the closing of its underwritten upsized public offering of 22,560,001 shares of its common stock. Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the transaction.

The upsized public offering includes the full exercise of the underwriters’ option to purchase 3,360,000 additional shares of its common stock, at a public offering price of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.00001 per share exercise price for each pre-funded warrant. All of the shares of common stock and pre-funded warrants in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.

The Wilson Sonsini team that advised Prime Medicine on IP matters related to the transaction included Lou Lieto, Clark Lin, Rachna Ujwal, Esther Cynn, and David Stanton.

For more information please see Prime Medicine’s press release.